+

WO2011156369A3 - Purification of modified cytokines - Google Patents

Purification of modified cytokines Download PDF

Info

Publication number
WO2011156369A3
WO2011156369A3 PCT/US2011/039439 US2011039439W WO2011156369A3 WO 2011156369 A3 WO2011156369 A3 WO 2011156369A3 US 2011039439 W US2011039439 W US 2011039439W WO 2011156369 A3 WO2011156369 A3 WO 2011156369A3
Authority
WO
WIPO (PCT)
Prior art keywords
purification
cytokine
modified cytokines
modified
cytokines
Prior art date
Application number
PCT/US2011/039439
Other languages
French (fr)
Other versions
WO2011156369A2 (en
Inventor
Darshan Koticha
Kishore Jahagirdhar
Original Assignee
Dr. Reddy's Laboratories Ltd.
Dr. Reddy's Laboratories, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr. Reddy's Laboratories Ltd., Dr. Reddy's Laboratories, Inc. filed Critical Dr. Reddy's Laboratories Ltd.
Publication of WO2011156369A2 publication Critical patent/WO2011156369A2/en
Publication of WO2011156369A3 publication Critical patent/WO2011156369A3/en

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/32—Bonded phase chromatography
    • B01D15/325—Reversed phase
    • B01D15/327—Reversed phase with hydrophobic interaction
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange

Landscapes

  • Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The application describes efficient methods of purifying a modified cytokine. The processes include the use of a chromatographic technique for the purification of the desired cytokine. The purified cytokine can be used to prepare therapeutic compositions.
PCT/US2011/039439 2010-06-07 2011-06-07 Purification of modified cytokines WO2011156369A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1567/CHE/2010 2010-06-07
IN1567CH2010 2010-06-07

Publications (2)

Publication Number Publication Date
WO2011156369A2 WO2011156369A2 (en) 2011-12-15
WO2011156369A3 true WO2011156369A3 (en) 2012-04-05

Family

ID=45098620

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/039439 WO2011156369A2 (en) 2010-06-07 2011-06-07 Purification of modified cytokines

Country Status (1)

Country Link
WO (1) WO2011156369A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140171626A1 (en) * 2012-12-19 2014-06-19 Glaxosmithkline Llc Protein purification
WO2014204023A1 (en) * 2013-06-17 2014-12-24 씨제이헬스케어 주식회사 Novel purification method for darbepoetin alpha
KR101414897B1 (en) * 2013-11-29 2014-07-04 씨제이헬스케어 주식회사 A method for purifying darbepoetin alfa
JP6906497B2 (en) * 2016-03-09 2021-07-21 Ｊｃｒファーマ株式会社 Method for producing mutant human erythropoietin

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641870A (en) * 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
EP1260518A1 (en) * 2000-03-02 2002-11-27 Kyowa Hakko Kogyo Co., Ltd. Method of separating and purifying protein
US20030023043A1 (en) * 2000-03-02 2003-01-30 Kazuhisa Uchida Method of separating and purifying protein
US20070037734A1 (en) * 2003-11-05 2007-02-15 Ares Trading S.A. Process for the purification of il-18 binding protein
US20080071067A1 (en) * 2006-09-20 2008-03-20 Avigenics, Inc. Methods of purifying proteins from egg white

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641870A (en) * 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US20050271654A1 (en) * 1995-04-20 2005-12-08 Genentech, Inc. Antibody purification
EP1260518A1 (en) * 2000-03-02 2002-11-27 Kyowa Hakko Kogyo Co., Ltd. Method of separating and purifying protein
US20030023043A1 (en) * 2000-03-02 2003-01-30 Kazuhisa Uchida Method of separating and purifying protein
US20070037734A1 (en) * 2003-11-05 2007-02-15 Ares Trading S.A. Process for the purification of il-18 binding protein
US20080071067A1 (en) * 2006-09-20 2008-03-20 Avigenics, Inc. Methods of purifying proteins from egg white

Also Published As

Publication number Publication date
WO2011156369A2 (en) 2011-12-15

Similar Documents

Publication Publication Date Title
WO2013078170A8 (en) Purification of anti-c-met antibodies
WO2010008823A3 (en) Purification of modified cytokines
EP3715345A3 (en) Preparation of lfa-1 inhibitor and polymorph thereof
IL214396A (en) Carba-nucleosides for antiviral treatment, pharmaceutical compositions comprising the same and methods of making carba-nucleosides and intermediates of carba-nucleosides for antiviral treatment
EP2850110A4 (en) Compositions containing purified non-hevea rubber and related purification methods
ZA201305971B (en) Method for the purification of biphephos
IL217999A0 (en) Chromatographic processes and purified compounds thereof
EP2578826A4 (en) Exhaust gas purification system
GB201301533D0 (en) Process for the synthesis and purification of oxycodone
PL2598228T3 (en) Methods and systems for solvent purification
IL216650A0 (en) Process for the preparation and purification of etravirine and intermediates thereof
WO2008021346A3 (en) Pure paliperidone and processes for preparing thereof
EP2959969A4 (en) Exhaust gas purifying catalyst and exhaust gas purification method using same
EP2578823A4 (en) Exhaust gas purification system
EP2578858A4 (en) Exhaust gas purification system
EP3318533A4 (en) Copper-supported zeolite and exhaust-gas purification treatment catalyst containing said zeolite
EP2581572A4 (en) Exhaust-gas purification system
WO2011156369A3 (en) Purification of modified cytokines
WO2011063195A3 (en) Purification of modified cytokines
IL228491A0 (en) Methods of purifying viruses using gel permeation chromatography
WO2013072933A3 (en) Process for preparation of 2-acetamido-n-benzyl-3-methoxypropionamide
EP2992955A4 (en) Exhaust-gas purification catalyst
ZA201306688B (en) Method for the purification of raw gas
EP2367836B8 (en) Process for the preparation and purification of topiramate
EP2516412A4 (en) Processes for the purification of lubiprostone

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11793017

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11793017

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载